Tradipitant GLP 1 vomiting trial reports 27 percent relative drop in Phase 3
Vanda Pharmaceuticals says its motion sickness drug Nereus lowered vomiting after a forced semaglutide dose in Phase 3, though the effect was smaller than in Phase 2 and full safety data are not public.
WASHINGTON
27%Relative reduction in any vomiting with Nereus versus placebo in Phase 3 Study 3601
- What's newVanda Pharmaceuticals said its oral NK1 blocker Nereus (tradipitant) met both main goals in Phase 3 Study 3601, with 43.0% vomiting on the drug against 58.5% on placebo after an untitrated semaglutide dose.
- Why it mattersNausea and vomiting are among the reasons people stop GLP 1 drugs, the company said. The Phase 3 effect was smaller than the 50% relative cut seen in Phase 2, and the trial did not measure whether people stayed on treatment.
- What's nextVanda plans to discuss the data with the FDA and file an sNDA, with no date given. Full results, safety tables and data in people titrating normally have not been released.
